Debt Financing

Baird Medical (BDMD) agrees to $4,347,826 convertible note with 8% discount

BDMD

Baird Medical Investment Holdings Limited agreed on September 24, 2026 to issue a US$4,347,826 senior convertible note to an investor. Net proceeds are about US$3.7 million.

Investor Chat

Scorecard

BDMDDebt
Deal Terms: 5/10, Fair termsHow favorable this deal is for the company and existing shareholders, compared with similar financings. · Terms are estimated from available structured facts. Unobserved components use the median prior; transaction linkage is incomplete. · As of 2026-11-08
Fair terms
Investor Impact: 8.2/10, Very highHow important this specific story was to investors when we published it, whether the news was good or bad. · High evidence · As of 2026-11-08
Very highHigh evidence
Company Deal Record: 5/10, Mixed recordHow favorable the company’s past financings have been, with more weight on recent deals. · As of 2026-11-08
Mixed record
Investment Attractiveness: 4.1/10, MixedThe company’s relative investment appeal, based on financial strength, valuation and execution. · Relative financial and execution position; not a forecast of stock returns. · As of 2026-11-08
Mixed

Convertible: $4,347,826 convertible notes

Market cap before$25.3MAfter (pro forma)$25.4MOwnership dilution0.3%Warrant coverage0%

By the aibio.space news desk

Rows of law books in a law library
Rows of law books in a law library. Photo: Jrcla2, Public domain, via Wikimedia Commons. The picture shows the field, not the companies named.

Baird Medical Investment Holdings Limited (Nasdaq: BDMD) signed a securities purchase agreement on September 24, 2026 with an investor. Under the agreement, the company agreed to issue a senior 8% original issue discount convertible promissory note in the principal amount of US$4,347,826. The company filed a prospectus supplement on September 24, 2026 and reported the agreement in a Form 6-K filed September 30, 2026. The prospectus supplement estimates net proceeds of about US$3.7 million after placement agent fees.

Why is this important: The note is debt that can turn into shares, so its dilution risk grows as the share price falls. The fixed conversion price is $0.9842, and the prospectus supplement puts the maximum at 27,517,886 shares if conversion happens at the floor price of $0.158. The note ranks ahead of the company's existing indebtedness and equity, so lenders and holders both have a claim to weigh.

Haimei Wu is the chairwoman and chief executive officer. The company's most recent annual report before this agreement is its Form 20-F filed April 24, 2026, which the company later amended on July 27, 2026. Its interim report shows cash of US$ 0.1 million at June 30, 2026, and restricted cash of US$ 0.2 million. Its no-substantial-doubt conclusion relies in part on Ms. Wu's support of US$ 2.0 million. In our view, a 12-month note that can convert at a floor price far below its fixed price asks holders to accept heavy dilution for short-term money, from a company whose unrestricted cash was this thin.

The terms in full

The principal is US$4,347,826. The note carries an 8% original issue discount and has a term of 12 months from issuance. No interest accrues unless an event of default occurs, in which case interest runs at 15% per annum or, if less, the highest rate the law allows. The company and each of its subsidiaries, other than an excluded subsidiary, entered into a subsidiary guarantee in favor of the investor.

The purchase agreement adds a 2% original issue discount of $86,956. The company settled it by issuing 110,070 ordinary shares at $0.79 per share. The same agreement obliges the investor to lend a further US$3,680,000 within 180 days, provided the closing price on the trading day before the second closing is more than $1.00. The investor may also lend up to $6 million more within 360 days, subject to mutual consent. The agreement provides for 1,500,000 pre-delivery shares to be issued to the investor so that it can convert the note.

Conversion, dilution and the placement agent

The fixed conversion price is $0.9842, which the prospectus supplement sets at 120% of the average of the three daily VWAPs on the trading day immediately before the closing date. The conversion price is the lower of that fixed price and an alternative price that applies when certain events occur. Beneficial ownership on conversion is capped at 9.99% of outstanding ordinary shares. At the floor price of $0.158, the maximum number of shares issuable on conversion is 27,517,886.

The dilution section uses 30,752,370 shares outstanding as of December 31, 2025, and cites a Nasdaq closing price of US$0.7901 on September 22, 2026. The offering section gives 32,002,370 ordinary shares outstanding immediately prior to this offering, a different count. The prospectus refers to placement agent fees but does not name the placement agent. The purchase agreement says no brokerage or finder's fees are payable by the company to any placement agent in connection with the transactions. The two documents do not reconcile on that point.

Business, the trials and what comes next

The interim report describes the company's principal business as research and development, manufacture and sales of microwave ablation (MWA) and other medical devices. The 20-F says that for Class III pipeline products the company must run clinical trials at its own expense unless an exemption applies. It names no specific clinical study, so the note does not rest on a clinical result.

The prospectus supplement cites a closing price of US$0.7901 for the ordinary shares and US$0.031 for the public warrants, which trade as BDMD W. On November 2, 2026 Nasdaq notified the company of a minimum bid price deficiency, which the company disclosed in a Form 6-K filed November 5, 2026. The company has until May 3, 2027 to regain compliance, and the second tranche depends on a closing price above $1.00.

Investor Chat

Loading posts…

Settings

Text size
Motion

Stops the moving share lists on the front page.

Your choices are saved in this browser only.

Free membership

Get aibio.space by email, free

Get updates from aibio.space by email. Sign up with your email address to receive updates and offers. Unsubscribe in one click.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address.